European Database Finds No Suicide Signal for GLP-1 Drugs
Disproportionality analysis of the European Pharmacovigilance database found no elevated signal for suicidal events with GLP-1 receptor agonists as a class.
Quick Facts
What This Study Found
Disproportionality analysis of the European Pharmacovigilance database found no elevated signal for suicidal events with GLP-1 receptor agonists as a class.
Key Numbers
230 reports of suicidal events identified over 5.5 years (January 2018 to July 2023). Reporting odds ratios were calculated for the GLP-1 RA class.
How They Did This
Retrospective pharmacovigilance study using disproportionality analysis (reporting odds ratios) of the European Pharmacovigilance database from January 2018 to July 2023.
Why This Research Matters
Millions of people take GLP-1 drugs, and a possible suicide link would be a major safety concern. This analysis helps put those concerns in perspective.
The Bigger Picture
Millions of people take GLP-1 drugs worldwide. A confirmed suicide link would be a major safety concern. This analysis helps put the question in perspective, showing no disproportionate signal in European safety data.
What This Study Doesn't Tell Us
Spontaneous reporting databases have known limitations including underreporting, reporting bias, and inability to establish causation. The analysis can only assess reporting patterns, not true incidence.
Questions This Raises
- ?Could rare subgroups be at higher risk despite no class-wide signal?
- ?Would a prospective study with mental health endpoints provide clearer answers?
Trust & Context
- Key Stat:
- No elevated signal Among 230 reports of suicidal events with GLP-1 drugs over 5.5 years, disproportionality analysis found no class-wide safety signal
- Evidence Grade:
- Rated moderate: pharmacovigilance database study using established disproportionality methodology. Spontaneous reporting databases have inherent limitations.
- Study Age:
- Published in 2024 analyzing data through July 2023. Addresses a question raised by regulatory agencies and media reports.
- Original Title:
- Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database.
- Published In:
- Pharmaceuticals (Basel, Switzerland), 17(2) (2024)
- Authors:
- Ruggiero, Rosanna, Mascolo, Annamaria, Spezzaferri, Angela, Carpentieri, Claudia, Torella, Daniele, Sportiello, Liberata, Rossi, Francesco, Paolisso, Giuseppe, Capuano, Annalisa
- Database ID:
- RPEP-09181
Evidence Hierarchy
Frequently Asked Questions
Do GLP-1 drugs like Ozempic cause suicidal thoughts?
European safety database analysis found no elevated signal for suicidal events with GLP-1 drugs as a class. Individual monitoring remains appropriate.
Should I worry about mental health on semaglutide?
Current evidence does not support a class-wide link to suicidal events. If you experience mental health changes, discuss them with your doctor.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09181APA
Ruggiero, Rosanna; Mascolo, Annamaria; Spezzaferri, Angela; Carpentieri, Claudia; Torella, Daniele; Sportiello, Liberata; Rossi, Francesco; Paolisso, Giuseppe; Capuano, Annalisa. (2024). Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database.. Pharmaceuticals (Basel, Switzerland), 17(2). https://doi.org/10.3390/ph17020147
MLA
Ruggiero, Rosanna, et al. "Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database.." Pharmaceuticals (Basel, 2024. https://doi.org/10.3390/ph17020147
RethinkPeptides
RethinkPeptides Research Database. "Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideat..." RPEP-09181. Retrieved from https://rethinkpeptides.com/research/ruggiero-2024-glucagonlike-peptide1-receptor-agonists
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.